Degenerative Disk Disease (DDD- osteochondrosis intervertebralis) is a common disorder that is characterized by progressive degeneration of the intervertebral disc; rendering them deformed and mechanically dysfunctional. It is a catchall phrase for a number of structural changes of the spine, such as loss of disc height, disc bulges, hydration, and impingement of nerves in the spine, among others.
Degenerative Disc Disease (DDD) can be diagnosed through imaging tests like X-rays, a magnetic resonance imaging scan (MRI) or computed tomography (CT) scan which can get a better look at the discs and bony structure. Degenerative Disc Disease (DDD) can often be managed conservatively through physical therapy, chiropractic manipulative therapy, osteopathic manipulation, anti-inflammatory medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), and/or spinal injections, epidural steroid injections that can provide pain relief. If these more moderate approaches fail to alleviate symptoms, surgery may be necessary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/degenerative-disc-disease-ddd-market
The Degenerative Disc Disease (DDD) Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Degenerative Disc Disease (DDD) market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Degenerative Disc Disease (DDD) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Degenerative Disc Disease (DDD) Market Key Facts
As per the study conducted by Bruin et al. (2018), Degenerative changes were found in 456/648 patients (70.4%). Degenerated discs and Schmorls nodes had the highest prevalence and were present in 278/648 patients (42.9%) and 238/648 patients (36.7%), respectively.
Chronic low back pain (CLBP) affects approximately 10-15% of the adult population, equivalent to more than 30 million people in the United States and almost 40 million people across the EU5. Also, as per the research study conducted by Michael et al. (2011) and Bao-Gan Peng (2013) approximately 7 million patients in each of the United States and EU-5 are thought to suffer from CLBP caused by degenerative disc disease.
As per the study conducted by Brinjikji et al. (2014), the prevalence of disk degeneration in asymptomatic individuals increased from 37% of 20-year-old individuals to 96% of 80-year-old individuals. Disk bulge prevalence increased from 30% of those 20 years of age to 84% of those 80 years of age. Disk protrusion prevalence increased from 29% of those 20 years of age to 43% of those 80 years of age. The prevalence of annular fissure increased from 19% of those 20 years of age to 29% of those 80 years of age.
Key Benefits of Degenerative Disc Disease (DDD) Market Report
Degenerative Disc Disease (DDD) market report provides an in-depth analysis of Degenerative Disc Disease Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.
The report will help in developing business strategies by understanding the Degenerative Disc Disease (DDD) Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.
The market report covers the Degenerative Disc Disease current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.
The report provides a detailed assessment of the Degenerative Disc Disease (DDD) market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
The Degenerative Disc Disease Market Size is expected to increase during the forecast period owing to the increasing incident pool, rising funding, clinical trials of degenerative disk disease, and expected entries of emerging therapies in the 7MM. The advances in understanding cell biology will contribute to the development of novel therapeutics for degenerative disk disease and also to the growth of the market.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Degenerative Disc Disease (DDD) market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Degenerative Disc Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Degenerative Disc Disease Market Drivers
Rich emerging pipeline
Increasing Incidence of Degenerative Disc Disease
Increasing cause of low back pains & neck pain in adults
Increasing geriatric population
Degenerative Disc Disease Epidemiology
The epidemiology section covers insights about the historical and current Degenerative Disc Disease (DDD) patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Degenerative Disc Disease Epidemiology Segmentation
Total Prevalent Cases of Degenerative Disk Disease
Total Prevalent Cases of Chronic low back pain
Diagnosed Cases of Degenerative Disk Disease
Treated Cases of Degenerative Disk Disease
Age-specific Cases and Gender-specific Cases of Degenerative Disk Disease
Severity-specific Cases of Degenerative Disk Disease
Degenerative Disc Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Degenerative Disc Disease (DDD) market or expected to get launched in the market during the study period. The analysis covers Degenerative Disc Disease (DDD) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Degenerative Disc Disease (DDD) Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Degenerative Disc Disease (DDD) market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Degenerative Disc Disease (DDD) emerging therapies.
The dynamics of the Degenerative Disk Disease market is anticipated to change in the coming years owing to the improvement in healthcare spending across the world. Some of the key players are involved in developing drugs for Degenerative Disk Disease (DDD) and associated conditions.
The companies marking drugs in the pipeline are mostly focused on minimally invasive regenerative medicine with the use of advanced technologies in order to gain substantial treatment modalities by focusing on disc regeneration.
Degenerative Disc Disease (DDD) Companies
And many others.
Degenerative Disc Disease (DDD) Therapies covered in the report include:
And many more.
The pipeline for degenerative disk disease brings a positive ray of hope for potential treatment options in the market in the upcoming years. The current scenario also anticipates a positive shift in the market in the coming years.
Table of Content
1. Key Insights
2. Executive Summary
3. Degenerative Disc Disease (DDD) Competitive Intelligence Analysis
4. Degenerative Disc Disease (DDD) Market Overview at a Glance
5. Degenerative Disc Disease (DDD) Disease Background and Overview
6. Degenerative Disc Disease (DDD) Patient Journey
7. Degenerative Disc Disease (DDD) Epidemiology and Patient Population
8. Degenerative Disc Disease (DDD) Treatment Algorithm, Current Treatment, and Medical Practices
9. Degenerative Disc Disease (DDD) Unmet Needs
10. Key Endpoints of Degenerative Disc Disease (DDD) Treatment
11. Degenerative Disc Disease (DDD) Marketed Products
12. Degenerative Disc Disease (DDD) Emerging Therapies
13. Degenerative Disc Disease (DDD) Seven Major Market Analysis
14. Attribute Analysis
15. Degenerative Disc Disease (DDD) Market Outlook (7 major markets)
16. Degenerative Disc Disease (DDD) Access and Reimbursement Overview
17. KOL Views on the Degenerative Disc Disease (DDD) Market.
18. Degenerative Disc Disease (DDD) Market Drivers
19. Degenerative Disc Disease (DDD) Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Migraines Therapeutics Market
As per the Migraine Research Foundation, Migraine is an extraordinarily prevalent neurological disease, affecting 39 million men, women, and children in the US. Similarly, worldwide around 1 billion people are supposed to be affected by it. Migraine has a direct/indirect impact on educational achievement, productivity, career progress, and financial status, responsibilities, and interpersonal dynamics of the affected individuals. Apart from these, it also impacts the health care system and the country’s economy as well. At present to provide effective treatment options some of the key companies such as Axsome Therapeutics, Impel NeuroPharma, Zosano Pharma, and many others are actively involved in the therapeutics development. For more details, visit: Migraines Therapeutics Market
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States